Published: May 13, 2021 By Alex Keown
Akouos, Inc. – Kathy Reape was named chief development officer of Boston-based Akouos. Reape most recently served as chief medical officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance, and medical affairs activities. Reape was a key member of the team responsible for the development and commercialization of Luxturna, the first FDA-approved in vivo gene therapy approved for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. Prior to Spark, Reape was senior vice president of clinical development focusing on global brands research and development at Allergan and Actavis.
CARMAT – France-based CARMAT’s board of directors is reorganizing its governance and appointed three new directors. The company tapped Florent Battistella, David Coti and John B. Hernandez as directors. Battistella founded Nisima, a holding company, which holds stakes in various firms, notably
Search jobs 11-May-2021 CORRECTING and REPLACING Former FDA and NIH Leader Dr. Vicki Seyfert-Margolis Joins Penrose TherapeuTx Scientific Advisory Board
Penrose scientific advisory board includes prominent research and regulatory experts in oncology, immunology and mitochondrial science
ANN ARBOR, Mich. & CHICAGO (BUSINESS WIRE) Please replace the release with the following corrected version due to multiple revisions in the first and third paragraphs, as well as correcting all instances of MyOwnMed to My Own Med, Inc. in the release text and image caption.
The corrected release reads:
FORMER FDA AND NIH LEADER DR. VICKI SEYFERT-MARGOLIS JOINS PENROSE THERAPEUTX SCIENTIFIC ADVISORY BOARD
Penrose scientific advisory board includes prominent research and regulatory experts in oncology, immunology and mitochondrial science